Literature DB >> 17517832

Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.

Sabahattin Kaymakoglu1, Dilek Oguz, Gurden Gur, Selim Gurel, Ethem Tankurt, Galip Ersöz, Seren Ozenirler, Cem Kalayci, Sule Poturoglu, Yilmaz Cakaloglu, Atilla Okten.   

Abstract

Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of <400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17517832      PMCID： PMC1932537          DOI： 10.1128/AAC.00088-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.

Authors:  Jean-Pierre Zarski; Patrick Marcellin; Vincent Leroy; Christian Trepo; Didier Samuel; Nathalie Ganne-Carrie; Karl Barange; Valérie Canva; Michel Doffoel; Paul Cales
Journal:  J Hepatol       Date:  2006-04-18       Impact factor: 25.083

2.  A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.

Authors:  Henry Lik-Yuen Chan; Nancy Wai-Yee Leung; Alex Yui Hui; Vincent Wai-Sun Wong; Choong-Tsek Liew; Angel Mei-Ling Chim; Francis Ka-Leung Chan; Lawrence Cheung-Tsui Hung; Yuk-Tong Lee; John Siu-Lun Tam; Christopher Wai-Kei Lam; Joseph Jao-Yiu Sung
Journal:  Ann Intern Med       Date:  2005-02-15       Impact factor: 25.391

3.  Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.

Authors:  I Tatulli; R Francavilla; G L Rizzo; V Vinciguerra; E Ierardi; A Amoruso; C Panella; A Francavilla
Journal:  J Hepatol       Date:  2001-12       Impact factor: 25.083

4.  Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study.

Authors:  Teresa Santantonio; Grazia Anna Niro; Emanuele Sinisi; Gioacchino Leandro; Maria Insalata; Angela Guastadisegni; Domenico Facciorusso; Eleonora Gravinese; Angelo Andriulli; Giuseppe Pastore
Journal:  J Hepatol       Date:  2002-06       Impact factor: 25.083

5.  Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B.

Authors:  C Yurdaydin; H Bozkaya; H Cetinkaya; T Sahin; D Karaoğuz; M Törüner; O Erkan; A O Heper; E Erden; A M Bozdayi; O Uzunalimoğlu
Journal:  J Viral Hepat       Date:  2005-05       Impact factor: 3.728

6.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Authors:  George K K Lau; Teerha Piratvisuth; Kang Xian Luo; Patrick Marcellin; Satawat Thongsawat; Graham Cooksley; Edward Gane; Michael W Fried; Wan Cheng Chow; Seung Woon Paik; Wen Yu Chang; Thomas Berg; Robert Flisiak; Philip McCloud; Nigel Pluck
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

Review 7.  Current state of interferon therapy in the treatment of chronic hepatitis B.

Authors:  Michael P Manns
Journal:  Semin Liver Dis       Date:  2002       Impact factor: 6.115

8.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

Authors:  Patrick Marcellin; George K K Lau; Ferruccio Bonino; Patrizia Farci; Stephanos Hadziyannis; Rui Jin; Zhi-Meng Lu; Teerha Piratvisuth; Georgios Germanidis; Cihan Yurdaydin; Moises Diago; Selim Gurel; Ming-Yang Lai; Peter Button; Nigel Pluck
Journal:  N Engl J Med       Date:  2004-09-16       Impact factor: 91.245

Review 9.  Treatment of chronic hepatitis B: current challenges and future directions.

Authors:  Ruth Chin; Stephen Locarnini
Journal:  Rev Med Virol       Date:  2003 Jul-Aug       Impact factor: 6.989

10.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425
View more
  9 in total

1.  Combination treatment in HBeAg-negative chronic hepatitis B.

Authors:  Konstantinos Tziomalos
Journal:  World J Hepatol       Date:  2009-10-31

2.  Interferon and nucleoside analog combination therapy for hepatitis B.

Authors:  Masahito Minami; Takayuki Katayama; Rei Sendo; Takeshi Okanoue; Toshikazu Yoshikawa
Journal:  Clin J Gastroenterol       Date:  2010-02-23

Review 3.  Alpha-interferon treatment in hepatitis B.

Authors:  Aaron Shu Jeng Woo; Raymond Kwok; Taufique Ahmed
Journal:  Ann Transl Med       Date:  2017-04

4.  Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop.

Authors:  Ting-Tsung Chang; Dong Jin Suh
Journal:  Hepatol Int       Date:  2008-03-05       Impact factor: 6.047

5.  Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials.

Authors:  Wen-Cong Li; Mao-Rong Wang; Ling-Bo Kong; Wei-Guang Ren; Yu-Guo Zhang; Yue-Min Nan
Journal:  BMC Infect Dis       Date:  2011-06-09       Impact factor: 3.090

6.  Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials.

Authors:  William W L Wong; Petros Pechivanoglou; Josephine Wong; Joanna M Bielecki; Alex Haines; Aysegul Erman; Yasmin Saeed; Arcturus Phoon; Mina Tadrous; Mona Younis; Noha Z Rayad; Valeria Rac; Harry L A Janssen; Murray D Krahn
Journal:  Syst Rev       Date:  2019-08-19

Review 7.  Interferons and their use in persistent viral infections.

Authors:  Stéphane Chevaliez; Jean-Michel Pawlotsky
Journal:  Handb Exp Pharmacol       Date:  2009

8.  A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B.

Authors:  Jialing Zhou; Xiaoning Wu; Wei Wei; Hong You; Jidong Jia; Yuanyuan Kong
Journal:  Int J Environ Res Public Health       Date:  2016-07-21       Impact factor: 3.390

Review 9.  Economic evaluation of treatments for chronic hepatitis B.

Authors:  Astrid Wiens; Luana Lenzi; Rafael Venson; Maria Lúcia Alves Pedroso; Cassyano Januário Correr; Roberto Pontarolo
Journal:  Braz J Infect Dis       Date:  2013-07-10       Impact factor: 3.257
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.